125 related articles for article (PubMed ID: 8523980)
1. P-glycoprotein expression in the squamous cell carcinoma of the tongue base.
Rabkin D; Chhieng DC; Miller MB; Jennings T; Feustel P; Steiniger J; Parnes SM
Laryngoscope; 1995 Dec; 105(12 Pt 1):1294-9. PubMed ID: 8523980
[TBL] [Abstract][Full Text] [Related]
2. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of taxol in human head and neck tumors.
Gan Y; Wientjes MG; Schuller DE; Au JL
Cancer Res; 1996 May; 56(9):2086-93. PubMed ID: 8616855
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance.
Lee JJ; Hughes CS; Fine RL; Page RL
Cancer; 1996 May; 77(9):1892-8. PubMed ID: 8646690
[TBL] [Abstract][Full Text] [Related]
5. P-glycoprotein expression in squamous cell carcinoma of the oral and maxillofacial region.
Xie ZJ; Yang XF; Gu ZY; Wu QL
Chin J Dent Res; 2000 May; 3(1):23-6. PubMed ID: 11314336
[TBL] [Abstract][Full Text] [Related]
6. [Squamous-cell carcinoma of the tongue: treatment results and prognosis].
Zwetyenga N; Majoufre-Lefebvre C; Siberchicot F; Demeaux H; Pinsolle J
Rev Stomatol Chir Maxillofac; 2003 Feb; 104(1):10-7. PubMed ID: 12644785
[TBL] [Abstract][Full Text] [Related]
7. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response.
Ng IO; Liu CL; Fan ST; Ng M
Am J Clin Pathol; 2000 Mar; 113(3):355-63. PubMed ID: 10705815
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
[TBL] [Abstract][Full Text] [Related]
9. Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Hepatogastroenterology; 2008; 55(86-87):1530-6. PubMed ID: 19102336
[TBL] [Abstract][Full Text] [Related]
10. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of p53-related proteins predicts rapid growth rate of head and neck cancer.
Edström S; Cvetkovska E; Westin T; Young C
Laryngoscope; 2001 Jan; 111(1):124-30. PubMed ID: 11192880
[TBL] [Abstract][Full Text] [Related]
13. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
Beck WT; Grogan TM; Willman CL; Cordon-Cardo C; Parham DM; Kuttesch JF; Andreeff M; Bates SE; Berard CW; Boyett JM; Brophy NA; Broxterman HJ; Chan HS; Dalton WS; Dietel M; Fojo AT; Gascoyne RD; Head D; Houghton PJ; Srivastava DK; Lehnert M; Leith CP; Paietta E; Pavelic ZP; Weinstein R
Cancer Res; 1996 Jul; 56(13):3010-20. PubMed ID: 8674056
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of P-glycoprotein in endometrial adenocarcinoma.
Axiotis CA; Monteagudo C; Merino MJ; LaPorte N; Neumann RD
Am J Pathol; 1991 Apr; 138(4):799-806. PubMed ID: 1707232
[TBL] [Abstract][Full Text] [Related]
15. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
16. Loss of Fhit expression is a predictor of poor outcome in tongue cancer.
Lee JI; Soria JC; Hassan K; Liu D; Tang X; El-Naggar A; Hong WK; Mao L
Cancer Res; 2001 Feb; 61(3):837-41. PubMed ID: 11221865
[TBL] [Abstract][Full Text] [Related]
17. Peroxiredoxin I expression in tongue squamous cell carcinomas as involved in tumor recurrence.
Yanagawa T; Omura K; Harada H; Ishii T; Uwayama J; Nakaso K; Iwasa S; Koyama Y; Onizawa K; Yusa H; Yoshida H
Int J Oral Maxillofac Surg; 2005 Dec; 34(8):915-20. PubMed ID: 15955662
[TBL] [Abstract][Full Text] [Related]
18. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
19. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
[TBL] [Abstract][Full Text] [Related]
20. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance.
Chang HW; Chow V; Lam KY; Wei WI; Yuen A
Cancer; 2002 Jan; 94(2):386-92. PubMed ID: 11900224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
